MCID: NRN004
MIFTS: 56

Neuroendocrine Tumor malady

Categories: Endocrine diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Neuroendocrine Tumor

Aliases & Descriptions for Neuroendocrine Tumor:

Name: Neuroendocrine Tumor 12 14
Neuroendocrine Carcinoma 12 29 14
Neuroendocrine Tumors 52 42 69
Carcinoma, Neuroendocrine 42 69
Carcinoma Neuroendocrine 52
Neuroendocrine Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:169 DOID:1800
ICD10 33 D3A.8
ICD9CM 35 209 209-209.99
NCIt 47 C3809 C3773

Summaries for Neuroendocrine Tumor

Disease Ontology : 12 A carcinoma that derives from neuroendocrine cells.

MalaCards based summary : Neuroendocrine Tumor, also known as neuroendocrine carcinoma, is related to jejunal neuroendocrine tumor and gastrinoma. An important gene associated with Neuroendocrine Tumor is CHGA (Chromogranin A), and among its related pathways/superpathways are Neuroscience and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Afinitor and Sutent have been mentioned in the context of this disorder. Affiliated tissues include pancreas, lung and liver, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Wikipedia : 71 Neuroendocrine tumors (NETs) are neoplasms that arise from cells of the endocrine (hormonal) and nervous... more...

Related Diseases for Neuroendocrine Tumor

Diseases related to Neuroendocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 339)
id Related Disease Score Top Affiliating Genes
1 jejunal neuroendocrine tumor 32.9 CHGA SYP
2 gastrinoma 31.7 CALCA NKX2-1 RET
3 thyroiditis 30.5 ASCL1 ENO2
4 pheochromocytoma 30.4 ASCL1 CALCA CHGA CHGB ENO2 MEN1
5 autoimmune pancreatitis 30.0 CHGA GAST
6 gastrointestinal stromal tumor 29.8 CHGA ENO2 SDHD SYP
7 superior vena cava syndrome 29.5 CHGA ENO2 NCAM1 SYP
8 cystadenoma 29.3 ENO2 NCAM1 NTS SYP
9 aneurysm 29.2 CALCA CHGA MEN1 RET
10 pulmonary neuroendocrine tumor 12.2
11 pancreatic neuroendocrine tumor 12.2
12 neuroendocrine carcinoma of the cervix 12.1
13 gastrointestinal neuroendocrine tumor 12.0
14 esophageal neuroendocrine tumor 12.0
15 gastric neuroendocrine tumor 12.0
16 gastro-enteropancreatic neuroendocrine tumor 11.9
17 ileal neuroendocrine tumor 11.9
18 thymic neuroendocrine tumor 11.9
19 neuroendocrine tumor of the colon 11.9
20 gastric neuroendocrine tumor type 2 11.9
21 classic neuroendocrine tumor of appendix 11.8
22 laryngeal neuroendocrine tumor 11.8
23 anal neuroendocrine tumor 11.8
24 neuroendocrine tumor of the appendix 11.8
25 hereditary neuroendocrine tumor of small intestine 11.8
26 gallbladder neuroendocrine tumor 11.8
27 neuroendocrine tumor of anal canal 11.8
28 familial gastric type 1 neuroendocrine tumor 11.8
29 small intestine carcinoid neuroendocrine tumor 11.8
30 gastric neuroendocrine tumor type 3 11.8
31 gastric neuroendocrine tumor type 1 11.8
32 gastric neuroendocrine tumor type 4 11.8
33 middle ear neuroendocrine tumor 11.8
34 insulinoma 11.4
35 carcinoid syndrome 11.2
36 von hippel-lindau syndrome 11.2
37 retinoblastoma 11.2
38 goblet cell carcinoid 11.2
39 pancreatic cancer 11.2
40 duodenal gastrinoma 11.1
41 rectum neuroendocrine neoplasm 11.0
42 phaeochromocytoma 10.8
43 adrenal carcinoma 10.8
44 prostate neuroendocrine neoplasm 10.7
45 small intestine neuroendocrine neoplasm 10.7
46 ovary neuroendocrine neoplasm 10.7
47 breast neuroendocrine neoplasm 10.7
48 well-differentiated neuroendocrine neoplasm of corpus uteri 10.7
49 gastric neuroendocrine neoplasm 10.7
50 jejunal somatostatinoma 10.7

Graphical network of the top 20 diseases related to Neuroendocrine Tumor:



Diseases related to Neuroendocrine Tumor

Symptoms & Phenotypes for Neuroendocrine Tumor

MGI Mouse Phenotypes related to Neuroendocrine Tumor:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.93 NTS RET SDHD SST SSTR2 SYP
2 endocrine/exocrine gland MP:0005379 9.61 ASCL1 CCK CHGA CHGB GAST MEN1
3 nervous system MP:0003631 9.44 ASCL1 CCK CHGB ENO2 MEN1 NCAM1

Drugs & Therapeutics for Neuroendocrine Tumor

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Afinitor 17 46 EVEROLIMUS Novartis Approved March 2009
2
Sutent 17 46 SUNITINIB MALATE Pfizer Approved May 2011/ Approved January 2006

Drugs for Neuroendocrine Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 667)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
3
Dacarbazine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 4342-03-4 5351166
4
Vindesine Approved Phase 4 59917-39-4, 53643-48-4 40839
5
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1 347396-82-1 459903
6
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
7
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 159351-69-6 6442177
8
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
9
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 33069-62-4 36314
10
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53123-88-9 5284616 6436030 46835353
11
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99011-02-6 57469
12
Somatostatin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 38916-34-6, 51110-01-1 53481605
13
Pancrelipase Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 53608-75-6
14
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83150-76-9 383414 6400441
15
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
16
Sunitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 341031-54-7, 557795-19-4 5329102
17
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3 124-94-7 31307
18
Dasatinib Approved, Investigational Phase 4,Phase 2,Phase 1 302962-49-8 3062316
19
Sorafenib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
20
Trametinib Approved Phase 4,Phase 3,Phase 2,Phase 1 871700-17-3 11707110
21
Aldesleukin Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 85898-30-2, 110942-02-4
22
lanreotide Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 108736-35-2
23
Etanercept Approved, Investigational Phase 4 185243-69-0
24
Citalopram Approved Phase 4 59729-33-8 2771
25
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
26
nivolumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 946414-94-4
27
Bortezomib Approved, Investigational Phase 4,Phase 1,Phase 2 179324-69-7 387447 93860
28
Gefitinib Approved, Investigational Phase 4,Phase 2 184475-35-2 123631
29
Ramucirumab Approved, Investigational Phase 4,Phase 2,Phase 1 947687-13-0
30
Vorinostat Approved, Investigational Phase 4,Phase 2,Phase 1,Early Phase 1 149647-78-9 5311
31
Doxazosin Approved Phase 4 74191-85-8 3157
32
Phenoxybenzamine Approved Phase 4 59-96-1 4768
33
Aminolevulinic acid Approved Phase 4 106-60-5 137
34
Liraglutide Approved Phase 4 204656-20-2
35
Zinc Approved Phase 4 7440-66-6 32051 23994
36
Crizotinib Approved Phase 4,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
37
Olaparib Approved Phase 4,Phase 2 763113-22-0 23725625
38
Palbociclib Approved Phase 4,Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
39
Ceritinib Approved Phase 4,Phase 2 1032900-25-6
40
Lapatinib Approved March 2007, Investigational Phase 4,Phase 2,Early Phase 1 231277-92-2, 388082-78-8 208908 9941095
41 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 pancreatic polypeptide Phase 4,Phase 2,Phase 3,Phase 1
43 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
44 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1
45 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1
46 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1
47 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1
48 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 2425)
id Name Status NCT ID Phase
1 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376 Phase 4
2 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
3 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy in Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4
4 Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy Unknown status NCT00540930 Phase 4
5 RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation Completed NCT01317615 Phase 4
6 Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced Neuroendocrine Tumors Completed NCT01595009 Phase 4
7 Somatuline Autogel Preference and Health Economy Study Completed NCT00681187 Phase 4
8 Post-Operative Drainage Following Lymph Node Dissection Completed NCT00324272 Phase 4
9 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4
10 Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma Completed NCT01253759 Phase 4
11 Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Completed NCT01959711 Phase 4
12 Effect of Topical Imiquimod on Lentigo Maligna Completed NCT01161888 Phase 4
13 Evaluating the Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment Completed NCT00352885 Phase 4
14 Growth Factor/Insulin-like Growth Factor (GH/IGF)-1 Axis in Obese Subjects in Treatment With Orlistat Completed NCT00991926 Phase 4
15 Radiolabeled Molecules for Medullary Thyroid Cancer Recruiting NCT01915485 Phase 4
16 A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer Recruiting NCT01896479 Phase 4
17 Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China Recruiting NCT02842749 Phase 4
18 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4
19 Nonfunctional Pancreatic NET and PET Imaging Recruiting NCT02621541 Phase 4
20 Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study. Recruiting NCT01789281 Phase 4
21 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4
22 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4
23 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Recruiting NCT02626065 Phase 4
24 Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma Recruiting NCT02451488 Phase 4
25 Phenoxybenzamine Versus Doxazosin in PCC Patients Recruiting NCT01379898 Phase 4
26 Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream Recruiting NCT02685592 Phase 4
27 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4
28 Stereotactic Body Radiotherapy for Liver Tumors Active, not recruiting NCT01347333 Phase 4
29 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Active, not recruiting NCT01525550 Phase 4
30 Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients Active, not recruiting NCT02075606 Phase 4
31 Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors Active, not recruiting NCT02759718 Phase 4
32 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET Active, not recruiting NCT03083210 Phase 4
33 Stereotactic Body Radiotherapy for Head and Neck Tumors Active, not recruiting NCT01344356 Phase 4
34 TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Active, not recruiting NCT02379000 Phase 4
35 An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma Active, not recruiting NCT01898585 Phase 4
36 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Active, not recruiting NCT02068196 Phase 4
37 Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab Active, not recruiting NCT01515189 Phase 4
38 Interpersonal Therapy for Depression in Breast Cancer Active, not recruiting NCT01191580 Phase 4
39 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4
40 HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4
41 HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4
42 Pasireotide Treatment for Neuroendocrine Tumor Withdrawn NCT02779257 Phase 4
43 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3
44 Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors Unknown status NCT00227617 Phase 2, Phase 3
45 Study to Investigate the Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut Unknown status NCT00171873 Phase 3
46 The Role of Inhalations of Tranexamic Acid in Patients With Hemoptysis Unknown status NCT01496196 Phase 3
47 Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver Unknown status NCT00039234 Phase 3
48 Vaccine Therapy in Treating Patients With Primary Stage II Melanoma Unknown status NCT00005052 Phase 3
49 Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00006249 Phase 3
50 High-Dose or Low-Dose Interferon Alfa Compared With No Further Therapy Following Surgery in Treating Patients With Stage III Melanoma Unknown status NCT00002763 Phase 3

Search NIH Clinical Center for Neuroendocrine Tumor

Cochrane evidence based reviews: neuroendocrine tumors

Genetic Tests for Neuroendocrine Tumor

Genetic tests related to Neuroendocrine Tumor:

id Genetic test Affiliating Genes
1 Neuroendocrine Neoplasm 29

Anatomical Context for Neuroendocrine Tumor

MalaCards organs/tissues related to Neuroendocrine Tumor:

39
Pancreas, Lung, Liver, Breast, Endothelial, Thyroid, Prostate

Publications for Neuroendocrine Tumor

Articles related to Neuroendocrine Tumor:

(show top 50) (show all 1105)
id Title Authors Year
1
Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. ( 27942928 )
2017
2
Application of (68)Ga-DOTA-TATE PET/CT in metastatic neuroendocrine tumor of gastrointestinal origin. ( 28042252 )
2017
3
Growth rate of small pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: results from an endoscopic ultrasound based cohort study. ( 27975336 )
2017
4
Pancreatic neuroendocrine tumor with metastasis to the spleen: a case report. ( 28068959 )
2017
5
The role of 68Ga-DOTA-NOC PET/CT in evaluating neuroendocrine tumors: real-world experience from two large neuroendocrine tumor centers. ( 27922538 )
2017
6
Combined 18F-FDG PET/CT and 68Ga DOTATATE PET/CT "Superscan" in Metastatic Pancreatic Neuroendocrine Tumor. ( 27997429 )
2017
7
68Ga-DOTATATE PET/CT in Primary Hepatic Neuroendocrine Tumor. ( 28005645 )
2017
8
The impact of SSTR-directed PET/CT on the management of patients with neuroendocrine tumor: A systematic review and meta-analysis. ( 28082438 )
2017
9
Pancreatic Neuroendocrine Tumor Abnormally Secreting Procalcitonin. ( 27977635 )
2017
10
Whole exome sequencing of thymic neuroendocrine tumor with ectopic ACTH syndrome. ( 27913610 )
2017
11
Hepatobiliary and Pancreatic: A rare case of a well-differentiated neuroendocrine tumor in the bile duct with spontaneous regression diagnosed by EUS-FNA. ( 28052461 )
2017
12
A cumulative effect involving malfunction of the PTH1R and ATP4A genes explains a familial gastric neuroendocrine tumor with hypothyroidism and arthritis. ( 28474257 )
2017
13
Single-stage laparoscopic adrenalectomy for pheochromocytoma and enucleation of a pancreatic neuroendocrine tumor in Von Hippel-Lindau disease: A case report. ( 28515932 )
2017
14
Immunoregulatory Forkhead Box Protein p3-Positive Lymphocytes Are Associated with Overall Survival in Patients with Pancreatic Neuroendocrine Tumors. ( 26809747 )
2016
15
Extrahepatic biliary obstrution secondary to neuroendocrine tumor of the common hepatic duct. ( 27902955 )
2016
16
The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios. ( 27542673 )
2016
17
Two Cases of Rectal Neuroendocrine Tumor Resection Combined with Dissection of the Circular Muscle Layer Using the Endoscopic Submucosal Dissection Technique. ( 27990103 )
2016
18
Establishment and Characterization of a Human Neuroendocrine Tumor Xenograft. ( 27067082 )
2016
19
Ablating all three retinoblastoma family members in mouse lung leads to neuroendocrine tumor formation. ( 27966456 )
2016
20
The uncovering and characterization of a CCKoma syndrome in enteropancreatic neuroendocrine tumor patients. ( 27191542 )
2016
21
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. ( 27582247 )
2016
22
Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization using Streptozotocin: A 20-Year Experience. ( 27663565 )
2016
23
Primary mesenteric neuroendocrine tumor that changed its internal composition from cystic to solid: a case report. ( 28028783 )
2016
24
Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors. ( 26474434 )
2016
25
An Ulcer of the Duodenum in an Adolescent Caused by a Pancreatic Neuroendocrine Tumor. ( 27613258 )
2016
26
Contrast-enhancement ratio on multiphase enhanced computed tomography predicts recurrence of pancreatic neuroendocrine tumor after curative resection. ( 26850565 )
2016
27
Intra-pancreatic Accessory Spleen Mimicking Pancreatic Neuroendocrine Tumor on 68-Ga-Dotatate PET/CT. ( 27845553 )
2016
28
A Neuroendocrine Tumor Invading All Portal Venous System Components. ( 27018107 )
2016
29
Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. ( 27635672 )
2016
30
Primary intracranial neuroendocrine tumor: two case reports. ( 27138163 )
2016
31
Initial Experience with CT-Guided High-Dose-Rate Brachytherapy in the Multimodality Treatment of Neuroendocrine Tumor Liver Metastases. ( 27645463 )
2016
32
Cerebellar dysfunction and spastic paraparesis associated to anti-Ri antibodies in a patient with a pancreatic neuroendocrine tumor. ( 27591774 )
2016
33
Systematic Review on the Role of Targeted Therapy in Metastatic Neuroendocrine Tumor (NET). ( 27082107 )
2016
34
Synchronous Quadruple Primary Neoplasms: Colon Adenocarcinoma, Collision Tumor of Neuroendocrine Tumor and Schwann Cell Hamartoma and Sessile Serrated Adenoma of the Appendix. ( 27466549 )
2016
35
Pasireotide Therapy of Multiple Endocrine Neoplasia Type 1-Associated Neuroendocrine Tumors in Female Mice Deleted for an Men1 Allele Improves Survival and Reduces Tumor Progression. ( 26990064 )
2016
36
Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. ( 27520932 )
2016
37
A Rare Case of Concomitant Intramedullary Gangliocytoma at the Cervicomedullary Junction in Patient with Neuroendocrine Tumor of Lung. ( 26962423 )
2016
38
Detection of neuroendocrine tumors using promoter-specific secreted Gaussia luciferase. ( 26530405 )
2016
39
Different Hormonal Expression Patterns Between Primary Pancreatic Neuroendocrine Tumors and Metastatic Sites. ( 26684862 )
2016
40
A rare case of metastasized non-functional pancreatic neuroendocrine tumor with a good long-term survival. ( 27928440 )
2016
41
Unusual Use of Gd-EOB-DTPA in MRCP in Order to Reveal the Source of Bile Leakage in a Patient with Neuroendocrine Tumor - Case Report. ( 27920840 )
2016
42
Expression of Sex Determining Region Y-Box 2 and Pancreatic and Duodenal Homeobox 1 in Pancreatic Neuroendocrine Tumors. ( 26491904 )
2016
43
Hand-assisted laparoscopic spleen-preserving distal pancreatectomy combined with laparoscopic distal gastrectomy for the treatment of pancreatic neuroendocrine tumor with early gastric cancer: Report of a case. ( 27756027 )
2016
44
A Rare Case of Mixed Neuroendocrine Tumor and Adenocarcinoma of the Pancreas. ( 27610261 )
2016
45
Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors. ( 26684860 )
2016
46
Extrathyroidal Calcitonin Secreting Tumors: Pancreatic Neuroendocrine Tumors in Patients With Multinodular Goiter: Two Case Reports. ( 26817871 )
2016
47
A recurrence of pancreatic non-functioning neuroendocrine tumor mimicking splenosis. ( 27931105 )
2016
48
Identification of human somatostatin receptor 2 domains involved in internalization and signaling in QGP-1 pancreatic neuroendocrine tumor cell line. ( 27406390 )
2016
49
Neuroendocrine tumor of distal bile duct. ( 28050084 )
2016
50
Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumors. ( 26712902 )
2016

Variations for Neuroendocrine Tumor

Copy number variations for Neuroendocrine Tumor from CNVD:

7 (show all 16)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 46474 10 81600000 81900000 Gain or loss C10orf57 Neuroendocrine carcinoma
2 46475 10 81600000 81900000 Gain or loss PLAC9 Neuroendocrine carcinoma
3 46476 10 81600000 81900000 Gain or loss SFTPD Neuroendocrine carcinoma
4 98126 16 15400000 16800000 Duplication ABCC1 Neuroendocrine carcinoma
5 98127 16 15400000 16800000 Duplication ABCC6 Neuroendocrine carcinoma
6 98128 16 15400000 16800000 Duplication C16orf45 Neuroendocrine carcinoma
7 98129 16 15400000 16800000 Duplication C16orf63 Neuroendocrine carcinoma
8 98130 16 15400000 16800000 Duplication KIAA0430 Neuroendocrine carcinoma
9 98131 16 15400000 16800000 Duplication MYH11 Neuroendocrine carcinoma
10 98132 16 15400000 16800000 Duplication NDE1 Neuroendocrine carcinoma
11 109503 17 26446120 26728821 Microdeletion NF1 Neuroendocrine carcinoma
12 111157 17 35097918 35138441 Gain HER-2/neu Neuroendocrine carcinoma
13 122931 18 64000000 64040000 Deletion Neuroendocrine carcinoma
14 160839 22 16300000 24300000 Microdeletion Neuroendocrine carcinoma
15 226129 7 55054218 55242525 Gain EGFR Neuroendocrine carcinoma
16 248801 9 137300000 137400000 Duplication C9orf62 Neuroendocrine carcinoma

Expression for Neuroendocrine Tumor

Search GEO for disease gene expression data for Neuroendocrine Tumor.

Pathways for Neuroendocrine Tumor

Pathways related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.94 CALCA ENO2 NCAM1 NKX2-1 RET SYP
2 11.67 ASCL1 RET SST SSTR2
3 11.34 ASCL1 NCAM1 SYP
4 9.64 CCK GAST GRP

GO Terms for Neuroendocrine Tumor

Cellular components related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 CALCA CCK CHGA ENO2 GAST GRP
2 extracellular region GO:0005576 9.65 CALCA CCK CHGA CHGB GAST GRP
3 secretory granule GO:0030141 9.5 CHGA CHGB SCG2
4 terminal bouton GO:0043195 9.43 CALCA CCK SYP
5 neuronal cell body GO:0043025 9.1 ASCL1 CALCA CCK ENO2 RET SST

Biological processes related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.62 MEN1 NCAM1 RET SCG2
2 neuron migration GO:0001764 9.58 ASCL1 CCK NKX2-1
3 neuropeptide signaling pathway GO:0007218 9.54 CALCA GRP SSTR2
4 cellular protein metabolic process GO:0044267 9.46 CALCA CHGB MEN1 SCG2
5 forebrain neuron differentiation GO:0021879 9.26 ASCL1 NKX2-1
6 positive regulation of phospholipase C-activating G-protein coupled receptor signaling pathway GO:1900738 8.96 CHGA GRP
7 cerebral cortex GABAergic interneuron differentiation GO:0021892 8.62 ASCL1 NKX2-1

Molecular functions related to Neuroendocrine Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.13 CCK GRP NTS
2 hormone activity GO:0005179 9.02 CALCA CCK CHGB GAST SST

Sources for Neuroendocrine Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....